Progress in technology of long-acting preparations of protein and peptide drugs

DING Yuan; CHEN Xin; TU Jiasheng; SUN Chunmeng

doi:10.11665/j.issn.1000-5048.20200407

Journal of China Pharmaceutical University > 2020 > 51(4): 433-440. > DOI: 10.11665/j.issn.1000-5048.20200407

DING Yuan, CHEN Xin, TU Jiasheng, SUN Chunmeng. Progress in technology of long-acting preparations of protein and peptide drugs[J]. Journal of China Pharmaceutical University, 2020, 51(4): 433-440. DOI: 10.11665/j.issn.1000-5048.20200407

Citation:

PDF (1796 KB)

Progress in technology of long-acting preparations of protein and peptide drugs

1.
Center for Research, Development and Evaluation for Pharmaceutical Excipients and Generic Drugs, China Pharmaceutical University, Nanjing 210009
2.
Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China

Funds: This study was supported by the National Natural Science Foundation of China (No.81972894, No.81673364), the Chinese Pharmacopoeia Commission “Reform of the Review and Approval System for Drugs and Medical Devices” Project (No.ZG2017-5-03) and the National Science and Technology Major Project for Drug Innovation (No.2017ZX09101001006)

More Information

Received Date: November 08, 2019

Graphical Abstract

Abstract

Abstract

As one of the most important biological drugs, protein and peptide drugs have been increasingly used in the prevention, diagnosis and treatment of diseases in recent years. However, most of them need to be injected and lack of long-acting formulations, which brings many troubles to patients suffering from chronic diseases. In this review, we summarized the strategies for engineering long-acting formulations for proteins and peptides via preparation means, including extended-release injection, implant, oral preparations and transdermal drug delivery systems, and analyzed their release mechanisms, research advances, advantages and shortcomings, thereby providing potential approaches for promoting the formulation improvement of these drugs.
- protein and peptide drugs,
- long-acting performance,
- extended- and controlled-release,
- formulation improvement,
- advances

FullText(HTML)

References (59)

References

[1]	Vaishya R, Khurana V, Patel S, et al. Long-term delivery of protein therapeutics[J]. Expert Opin Drug Deliv, 2015, 12(3):415-440.
[2]	Vaishya RD, Khurana V, Patel S, et al. Controlled ocular drug delivery with nanomicelles[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2014, 6(5):422-437.
[3]	Jia H, Guo Y, Song X, et al. Elimination of N-glycosylation by site mutation further prolongs the half-life of IFN-alpha/Fc fusion proteins expressed in Pichia pastoris[J]. Microb Cell Fact, 2016, 15(1):209.
[4]	Czajkowsky DM, Hu J, Shao Z, et al. Fc-fusion proteins: new developments and future perspectives[J]. EMBO Mol Med, 2012, 4(10):1015-1028.
[5]	Kim D, Jeon H, Ahn S, et al. An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide[J]. J Control Release, 2017, 256:114-120.
[6]	Li CY, Huang WL, Qian H. Advances in the research of long-acting strategy of insulin and GLP-1 analogs[J]. J China Pharm Univ(中国药科大学学报), 2018, 49(6):660-670.
[7]	Deyle K, Kong XD, Heinis C. Phage selection of cyclic peptides for application in research and drug development[J]. Acc Chem Res, 2017, 50(8):1866-1874.
[8]	Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes[J]. Diabetes Care, 2007, 30(6):1487-1493.
[9]	Oh YJ, Lee JW, Seo JY, et al. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model[J]. J Control Release, 2011, 150(1):56-62.
[10]	Zhang Y, Wischke C, Mittal S, et al. Design of controlled release PLGA microspheres for hydrophobic fenretinide[J]. Mol Pharm, 2016, 13(8):2622-2630.
[11]	Rosa GD, Iommelli R, La Rotonda MI, et al. Influence of the co-encapsulation of different non-ionic surfactants on the properties of PLGA insulin-loaded microspheres[J]. J Control Release, 2000, 69(2):283-295.
[12]	Bae SE, Son JS, Park K, et al. Fabrication of covered porous PLGA microspheres using hydrogen peroxide for controlled drug delivery and regenerative medicine[J]. J Control Release, 2009, 133(1):37-43.
[13]	Casalini T, Rossi F, Lazzari S, et al. Mathematical modeling of PLGA microparticles: from polymer degradation to drug release[J]. Mol Pharm, 2014, 11(11):4036-4048.
[14]	Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices[J]. Biomaterials, 2000, 21(23):2475-2490.
[15]	Díaz E, Puerto I, Ribeiro S, et al. The influence of copolymer composition on PLGA/nHA Scaffolds' cytotoxicity and in vitro degradation[J]. Nanomaterials (Basel), 2017, 7(7): 173.
[16]	Yang S, Yuan W, Jin T. Formulating protein therapeutics into particulate forms[J]. Expert Opin Drug Deliv, 2009, 6(10):1123-1133.
[17]	Wu JZ, Williams GR, Li HY, et al. Insulin-loaded PLGA microspheres for glucose-responsive release[J]. Drug Deliv, 2017, 24(1):1513-1525.
[18]	Jain A, Kunduru KR, Basu A, et al. Injectable formulations of poly(lactic acid) and its copolymers in clinical use[J]. Adv Drug Deliv Rev, 2016, 107:213-227.
[19]	Guo J, Sun X, Yin H, et al. Chitosan microsphere used as an effective system to deliver a linked antigenic peptides vaccine protect mice against acute and chronic toxoplasmosis[J]. Front Cell Infect Microbiol, 2018, 8:163.
[20]	Mantripragada S. A lipid based depot (DepoFoam^? technology) for sustained release drug delivery[J]. Prog Lipid Res, 2002, 41(5):392-406.
[21]	Bulbake U, Doppalapudi S, Kommineni N, et al. Liposomal formulations in clinical use: an updated review[J]. Pharmaceutics, 2017, 9(2): 12.
[22]	Lewis KA, Goldyn AK, West KW, et al. A single histrelin implant is effective for 2 years for treatment of central precocious puberty[J]. J Pediatr, 2013, 163(4):1214-1216.
[23]	Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy[J]. N Engl J Med, 2015, 372(10):923-932.
[24]	Zhao YN, Xu X, Wen N, et al. A drug carrier for sustained Zero-order release of peptide therapeutics[J]. Sci Rep, 2017, 7(1):5524.
[25]	Jeong JW, McCall JG, Shin G, et al. Wireless optofluidic systems for programmable in vivo Pharmacology and optogenetics[J]. Cell, 2015, 162(3):662-674.
[26]	Farra R, Sheppard NF, McCabe L, et al. First-in-human testing of a wirelessly controlled drug delivery microchip[J]. Sci Transl Med, 2012, 4(122):122ra121.
[27]	Parent M, Clarot I, Gibot S, et al. One-week in vivo sustained release of a peptide formulated into in situ forming implants[J]. Int J Pharm, 2017, 521(1/2):357-360.
[28]	Brodbeck KJ, DesNoyer JR, McHugh AJ. Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer[J]. J Control Release, 1999, 62(3):333-344.
[29]	Huang LP, Li YN, Du YA, et al. Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy[J]. Nat Commun, 2019, 10(1):4871.
[30]	Ruel-Gariepy E, Leroux JC. In situ-forming hydrogels—review of temperature-sensitive systems[J]. Eur J Pharm Biopharm, 2004, 58(2):409-426.
[31]	Agarwal P, Rupenthal ID. Injectable implants for the sustained release of protein and peptide drugs[J]. Drug Discov Today, 2013, 18(7):337-349.
[32]	Singh NK, Lee DS. In situ gelling pH- and temperature-sensitive biodegradable block copolymer hydrogels for drug delivery[J]. J Control Release, 2014, 193:214-227.
[33]	Liu Y, Chen X, Li S, et al. Calcitonin-loaded thermosensitive hydrogel for long-term antiosteopenia therapy[J]. ACS Appl Mater Interfaces, 2017, 9(28):23428-23440.
[34]	Xu YR, Shen Y, Xiong YR, et al. Synthesis, characterization, biodegradability and biocompatibility of a temperature-sensitive PBLA-PEG-PBLA hydrogel as protein delivery system with low critical gelation concentration[J]. Drug Dev Ind Pharm, 2014, 40(9):1264-1275.
[35]	Feng Z, Zhao J, Li Y, et al. Temperature-responsive in situ nanoparticle hydrogels based on hydrophilic pendant cyclic ether modified PEG-PCL-PEG[J]. Biomater Sci, 2016, 4(10):1493-1502.
[36]	Lai MC, Chang KC, Hsu SC, et al. In situ gelation of PEG-PLGA-PEG hydrogels containing high loading of hydroxyapatite: in vitro and in vivo characteristics[J]. Biomed Mater, 2014, 9(1):015011.
[37]	Bobbala S, Tamboli V, McDowell A, et al. Novel injectable pentablock copolymer based thermoresponsive hydrogels for sustained release vaccines[J]. AAPS J, 2016, 18(1):261-269.
[38]	Wang C, Wang J, Zhang X, et al. In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy[J]. Sci Transl Med, 2018, 10(429):eaan3682.
[39]	Zhao Y, Cui Z, Liu B, et al. An injectable strong hydrogel for bone reconstruction[J]. Adv Healthc Mater, 2019, 8(17):e1900709.
[40]	Nguyen NT, Nguyen LV, Tran NM, et al. The effect of oxidation degree and volume ratio of components on properties and applications of in situ cross-linking hydrogels based on chitosan and hyaluronic acid[J]. Mater Sci Eng C Mater Biol Appl, 2019, 103:109670.
[41]	Criado-Gonzalez M, Corbella L, Senger B, et al. Photoresponsive nanometer-scale iron alginate hydrogels: a study of gel-sol transition using quartz crystal microbalance[J]. Langmuir, 2019, 35(35):11397-11405.
[42]	Gupta V, Hwang BH, Doshi N, et al. Delivery of exenatide and insulin using mucoadhesive intestinal devices[J]. Ann Biomed Eng, 2016, 44(6):1993-2007.
[43]	Gupta V, Hwang BH, Lee JH, et al. Mucoadhesive intestinal devices for oral delivery of salmon calcitonin[J]. J Control Release, 2013, 172(3):753-762.
[44]	Castro PM, Fonte P, Sousa F, et al. Oral films as breakthrough tools for oral delivery of proteins/peptides[J]. J Control Release, 2015, 211:63-73.
[45]	Salvioni L, Fiandra L, Del CMD, et al. Oral delivery of insulin via polyethylene imine-based nanoparticles for colonic release allows glycemic control in diabetic rats[J]. Pharmacol Res, 2016, 110:122-130.
[46]	Zhao XH, Shan C, Zu YG, et al. Preparation, characterization, and evaluation in vivo of Ins-SiO₂-HP55 (insulin-loaded silica coating HP55) for oral delivery of insulin[J]. Int J Pharm, 2013, 454(1):278-284.
[47]	Chuang EY, Lin KJ, Lin PY, et al. Self-assembling bubble carriers for oral protein delivery[J]. Biomaterials, 2015, 64:115-124.
[48]	Leonaviciute G, Bernkop-Schnurch A. Self-emulsifying drug delivery systems in oral (poly)peptide drug delivery[J]. Expert Opin Drug Deliv, 2015, 12(11):1703-1716.
[49]	Kusamori K, Katsumi H, Sakai R, et al. Development of a drug-coated microneedle array and its application for transdermal delivery of interferon alpha[J]. Biofabrication, 2016, 8(1):015006.
[50]	Lau S, Fei J, Liu H, et al. Multilayered pyramidal dissolving microneedle patches with flexible pedestals for improving effective drug delivery[J]. J Control Release, 2017, 265:113-119.
[51]	van der Maaden K, Heuts J, Camps M, et al. Hollow microneedle-mediated micro-injections of a liposomal HPV E743-63 synthetic long peptide vaccine for efficient induction of cytotoxic and T-helper responses[J]. J Control Release, 2018, 269:347-354.
[52]	Qiu YQ, Qin GJ, Zhang SH, et al. Novel lyophilized hydrogel patches for convenient and effective administration of microneedle-mediated insulin delivery[J]. Int J Pharm, 2012, 437(1):51-56.
[53]	Seong KY, Seo MS, Hwang DY, et al. A self-adherent, bullet-shaped microneedle patch for controlled transdermal delivery of insulin[J]. J Control Release, 2017, 265:48-56.
[54]	Chen MC, Huang SF, Lai KY, et al. Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination[J]. Biomaterials, 2013, 34(12):3077-3086.
[55]	Kim MY, Jung BK, Park JH. Hydrogel swelling as a trigger to release biodegradable polymer microneedles in skin[J]. Biomaterials, 2012, 33(2):668-678.
[56]	Ganesan P, Choi DK. Current application of phytocompound-based nanocosmeceuticals for beauty and skin therapy[J]. Int J Nanomedicine, 2016, 11:1987-2007.
[57]	Wu PS, Li YS, Kuo YC, et al. Preparation and evaluation of novel transfersomes combined with the natural antioxidant resveratrol[J]. Molecules, 2019, 24(3):600.
[58]	Carter P, Narasimhan B, Wang Q. Biocompatible nanoparticles and vesicular systems in transdermal drug delivery for various skin diseases[J]. Int J Pharm, 2019, 555:49-62.
[59]	Desai P, Patlolla RR, Singh M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery[J]. Mol Membr Biol, 2010, 27(7):247-259.

Cited By

Cited by

Periodical cited type(5)

1.	李昇原，黄永鹏，唐慧，汪春江，李秀兰，陈博. 白蛋白-奥曲肽纳米颗粒制备及其缓释性能. 中国粉体技术. 2023(01): 39-48 .
2.	张铭笑，孙春萌. 骨靶向药物递送系统研究进展. 药学进展. 2023(08): 637-644 .
3.	毛姝英，金蔚，付思思，刘珂安琪，周志豪，王广基，梁艳. 口服脾多肽改善氨水诱导的小鼠咳嗽和体内炎症. 中国临床药理学与治疗学. 2022(06): 601-607 .
4.	杨晓男，阮丽君，江兴，宋志军，韦坤华，秦双双，梁莹，侯小利，王喜军，缪剑华. 多肽类药物与中药肽研究展望. 中国中药杂志. 2022(22): 5978-5990 .
5.	白万军，孙晓利，赫立恩，董占军. 某院120例生化药品不良反应报告分析. 中国药业. 2021(21): 14-17 .

Other cited types(3)

Get Citation

PDF

XML

Article views (454) PDF downloads (1319) Cited by(8)

Turn off MathJax

Article Contents

Abstract

References

Progress in technology of long-acting preparations of protein and peptide drugs

Abstract

References

Cited by

Periodical cited type(5)

Other cited types(3)

Catalog

Export File

Citation

Format

Content